AUTHOR=Zhang Houliang , Wang Yidi , Ni Jinliang , Shi Huajuan , Zhang Tao , Zhang Yifan , Guo Jing , Wang Keyi , Mao Weipu , Peng Bo 

TITLE=Prognostic Value of Lymphocyte–C-Reactive Protein Ratio in Patients Undergoing Radical Cystectomy for Bladder Cancer: A Population-Based Study

JOURNAL=Frontiers in Oncology

VOLUME=Volume 11 - 2021

YEAR=2021

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.760389

DOI=10.3389/fonc.2021.760389

ISSN=2234-943X

ABSTRACT=Purpose: This study was aimed to assess the prognostic value of the lymphocyte-C-reactive protein ratio (LCR) in patients with bladder cancer (BCa) underwent radical cystectomy (RC).
Materials and methods: BCa patients between 2009 and 2018 were retrieved from our medical center. The predictive value of LCR on survival of BCa patients were evaluated through the Kaplan-Meier survival and receiver operating characteristic (ROC) curves. The multivariate cox regression results were used for the conducting of the nomogram, which was further verified by ROC, decision curve analysis (DCA) and calibration curves. Propensity score matching (PSM) was performed to validate our findings.
Results: A number of 201 BCa patients received RC were included in this study, with 62 (30.8%) patients were divided into the low LCR group and 139 (69.2%) into the high LCR group. Multivariate analysis results revealed the high LCR group was significantly related to better prognosis and functioned as a prognostic biomarker for overall survival (OS) [hazard ratio (HR) = 0.41, 95% confidence interval (CI) = 0.26-0.66, P<0.001] and disease-free survival (DFS) [HR = 0.40, 95% CI = 0.26-0.66, P<0.001]. The nomogram processed the better predictive capability and accuracy than TNM stage from ROC results (AUC=0.754 vs. AUC=0.715), with the confirmation of calibration curves and DCA analysis. The result of PSM comfiremed LCR was significantly correlated with OS and DFS.
Conclusion: Our finding manifested the LCR as a novel, convenient and effective predictor may provide the vital assistance for clinical decision and individualized therapy in BCa patients after RC.